Ghoul
Member
I think the goal is just to keep LDL as low as possible.
Going around chasing HDL is not beneficial.
Products that apparently improve higher quality HDL measured by CEC has been shown to not be beneficial.
The 2014 studies looks at the following, all of which i believe improve CEC, with CETP providing the strongest improvements.No.
Hundreds of studies after that 2014 paper went on to establish that cardiovascular risk is lowered by quality, not only quantity of HDL. HDL's ability to remove cholesterol, measured by CEC (cholesterol efflux capacity) and anti-inflammatory properties are what matters most.
In a different post i believe you ranked Niacin and Fibrates as well, right after Pita, both of which were also evaluated in the 2014 study...
Some products which drastically improve HDL, CEC and Apoa-I actually even cause more harm.
The 2014 studies looks at the following, all of which i believe improve CEC, with CETP providing the strongest improvements.
View attachment 339122
View attachment 339130
View attachment 339131
In a different post i believe you ranked Niacin and Fibrates as well, right after Pita, both of which were also evaluated in the 2014 study as not being beneficial.
Edit, found it
Interesting read about CETP. I havnt heard of it before, but it looks like it does boost apoA1...
The main suspect with those compounds is that they don't raise ApoA-I enough, compared to the massive increase in HDL (75%+) so the end result is a large quantity of low quality "more harm than benefit HDL".
Pita only raises HDL slightly, 5-10%, and ApoA-I modestly, but enough to ensure the HDL produced is high quality. So when HDL function (aka 'HDL efflux capacity') is measured post Pitavastatin, it's confirmed that it's improved. Obviously you wouldn't switch to Pita for a big increase in HDL, it's more of a nice bonus if you're deciding between statins, and reassuring to know it's producing "good HDL".

Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients - PubMed
In addition to its LDL-C-lowering effects, pitavastatin elevates the HDL-C level and enhances the cholesterol efflux capacity and antioxidative properties of HDL. Pitavastatin therefore increases the amount of functional HDL without attenuating HDL quality.



